Tags

Type your tag names separated by a space and hit enter

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Clin Infect Dis. 2002 Jun 01; 34(11):1460-8.CI

Abstract

We conducted a prospective, randomized, double-blind trial comparing ertapenem (1 g once daily) with piperacillin-tazobactam (3.375 g every 6 h) as parenteral treatment for 540 adults with complicated skin and skin-structure infections. The most common diagnoses were skin or soft-tissue abscesses and lower-extremity infections associated with diabetes. The mean duration (+/- standard deviation) of therapy was 9.1+/-3.1 days for ertapenem and 9.8+/-3.3 days for piperacillin-tazobactam. At the assessment of primary efficacy end point, 10-21 days after treatment, 82.4% of those who received ertapenem and 84.4% of those who received piperacillin-tazobactam were cured. The difference in response rates, adjusting for the patients' assigned strata, was -2.0% (95% confidence interval, -10.2% to 6.2%), indicating that the response rates in the 2 treatment groups were equivalent. Cure rates for the 2 treatment groups were similar when compared by stratum, diagnosis, and severity of infection. The frequency and severity of drug-related adverse events were similar in the treatment groups.

Authors+Show Affiliations

Springfield Clinic, Springfield, IL, 62703, USA. infectn@springfieldclinic.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12015692

Citation

Graham, Donald R., et al. "Ertapenem once Daily Versus Piperacillin-tazobactam 4 Times Per Day for Treatment of Complicated Skin and Skin-structure Infections in Adults: Results of a Prospective, Randomized, Double-blind Multicenter Study." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 34, no. 11, 2002, pp. 1460-8.
Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34(11):1460-8.
Graham, D. R., Lucasti, C., Malafaia, O., Nichols, R. L., Holtom, P., Perez, N. Q., McAdams, A., Woods, G. L., Ceesay, T. P., & Gesser, R. (2002). Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 34(11), 1460-8.
Graham DR, et al. Ertapenem once Daily Versus Piperacillin-tazobactam 4 Times Per Day for Treatment of Complicated Skin and Skin-structure Infections in Adults: Results of a Prospective, Randomized, Double-blind Multicenter Study. Clin Infect Dis. 2002 Jun 1;34(11):1460-8. PubMed PMID: 12015692.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. AU - Graham,Donald R, AU - Lucasti,Christopher, AU - Malafaia,Osvaldo, AU - Nichols,Ronald L, AU - Holtom,Paul, AU - Perez,Nora Quintero, AU - McAdams,Andrea, AU - Woods,Gail L, AU - Ceesay,T Paulette, AU - Gesser,Richard, Y1 - 2002/05/09/ PY - 2001/09/20/received PY - 2002/01/08/revised PY - 2002/5/17/pubmed PY - 2002/5/22/medline PY - 2002/5/17/entrez SP - 1460 EP - 8 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 34 IS - 11 N2 - We conducted a prospective, randomized, double-blind trial comparing ertapenem (1 g once daily) with piperacillin-tazobactam (3.375 g every 6 h) as parenteral treatment for 540 adults with complicated skin and skin-structure infections. The most common diagnoses were skin or soft-tissue abscesses and lower-extremity infections associated with diabetes. The mean duration (+/- standard deviation) of therapy was 9.1+/-3.1 days for ertapenem and 9.8+/-3.3 days for piperacillin-tazobactam. At the assessment of primary efficacy end point, 10-21 days after treatment, 82.4% of those who received ertapenem and 84.4% of those who received piperacillin-tazobactam were cured. The difference in response rates, adjusting for the patients' assigned strata, was -2.0% (95% confidence interval, -10.2% to 6.2%), indicating that the response rates in the 2 treatment groups were equivalent. Cure rates for the 2 treatment groups were similar when compared by stratum, diagnosis, and severity of infection. The frequency and severity of drug-related adverse events were similar in the treatment groups. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/12015692/Ertapenem_once_daily_versus_piperacillin_tazobactam_4_times_per_day_for_treatment_of_complicated_skin_and_skin_structure_infections_in_adults:_results_of_a_prospective_randomized_double_blind_multicenter_study_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/340348 DB - PRIME DP - Unbound Medicine ER -